Eli Lilly revealed positive clinical trial outcomes for 'orforglipron', a daily pill intended to combat obesity and diabetes. Despite the drug's promising efficacy and minimal side effects, its name has drawn criticism for being excessively complicated and hard to pronounce. This isn't the first time drug names have sparked outrage; the pharmaceutical industry is notorious for such choices. Poor naming can lead to dangerous medication errors, and drug naming involves adhering to a strict set of international guidelines and avoiding confusing terminology.
In a market flooded with intricate drug names, Eli Lilly's 'orforglipron' stands out as a perplexing choice, raising questions about whether it can ever be popularized.
The naming process for drugs like 'orforglipron' is rigorous, with rules dictating what letters can and cannot be used to avoid confusion and ensure safety.
Collection
[
|
...
]